SAB Biotherapeutics has reported that its antibody SAB-185 for Covid-19 retained neutralisation activity against the Omicron variant of SARS-CoV-2 in an in vitro pseudovirus model.
The National Institutes of Health (NIH) has commenced subject enrolment in a Phase II/III ACTIV-2 trial of a new fully human polyclonal antibody therapeutic called SAB-185 for treating Covid-19 in non-hospitalised individuals with mild or moderate ...
SAB Biotherapeutics, a US-based clinical-stage company, has dosed the first participant of a phase 1 study of SAB-185, its therapeutic candidate for Covid-19, in healthy volunteers.